The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Stocks•27 May 2026•

1 min read

William Blair Initiates Insulet with Outperform Rating Amid GLP-1 Concerns

Key Facts

1William Blair analyst Steve Lichtman initiated coverage on Insulet with an Outperform rating.

2The analyst argues the valuation gap between Insulet and its peers is hard to justify despite near-term growth risks.

3The report highlighted growth catalysts including salesforce expansion and new product development.

In a move reflecting optimism in the future of healthcare technology, William Blair analyst Steve Lichtman initiated coverage on Insulet with an Outperform rating. The analyst argues that the valuation gap between the company and its industry peers is currently unjustified, despite some near-term growth risks. The report also highlighted key growth catalysts, including the expansion of the salesforce and continued development of innovative products.

This initiation comes as the medical device sector faces pressure from the widespread adoption of GLP-1 drugs, with Insulet's stock declining significantly over the past year compared to peers like Dexcom and Tandem Diabetes. According to market data, investors are closely monitoring how these drugs impact long-term demand for insulin pumps, but William Blair suggests the recent selloff has created an attractive entry point at current valuation levels.

Traders should watch PODD stock levels, which stood at $174.20 (close May 27, 2026), for any technical rebound following this positive catalyst. Looking at the economic calendar, attention will turn to the upcoming U.S. Manufacturing and Services PMI data, which could influence risk appetite across the growth and biotech sectors.